ESC 2026 Special: JACC SimPub Papers You Should Know | JACC Baran
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
ESC 2026 Special: JACC SimPub Papers You Should Know | JACC Baran
-
Letto da:
-
Di:
Hosts Mitsuaki Sawano, MD, Takeshi Kitai, MD, PhD, Kentaro Ejiri, MD, PhD, and Satoshi Shoji, MD, PhD, highlight three JACC papers presented at ESC 2026 and simultaneously published with the meeting. Dr. Kitai discusses new HELIOS-B insights on whether the benefits of vutrisiran in transthyretin amyloidosis with cardiomyopathy are maintained among patients already receiving tafamidis. Dr. Ejiri reviews a nationwide Swedish study of nearly 500,000 heart failure hospitalizations examining how cold spells, heat waves, and non-optimal temperatures influence short-term HF risk, including the different timing of risk after rising versus falling temperatures. Dr. Shoji explores how lepodisiran, an extended-duration siRNA targeting lipoprotein(a), markedly reduces oxidized phospholipids carried by Lp(a), providing further insight into the mechanisms linking Lp(a) with cardiovascular risk. The team discusses what these findings add to current evidence, how they may translate to clinical practice in Japan, and the key questions that remain.